论文部分内容阅读
目的观察含卡培他滨方案对蒽环类和(或)紫杉类药物治疗后复发转移性乳腺癌的疗效和不良反应。方法 70例蒽环类和(或)紫杉类药物治疗后复发转移性乳腺癌患者分为两组,卡培他滨联合长春瑞滨(NX组,36例),卡培他滨800～1000mg/m2,分早晚两次服用,第1～14天,长春瑞滨25mg/m2,第1天和第8天,静脉滴注,3周为1个周期。卡培他滨联合吉西他滨(GX组,34例),卡培他滨800～1000mg/m2,分早晚两次服用,第1～14天,吉西他滨1g/m2,静脉滴注,第1天和第8天,3周为1个周期。每两个周期评价疗效,均至少治疗2个周期以上。结果 NX组患者中,完全缓1例(2.8%),部分缓解20例(55.6%),疾病稳定11例(30.6%),疾病进展4例(11.1%),有效率为58.3%,中位疾病进展时间13.5个月;完全缓解1例(2.9%),部分缓解19例(55.9%),疾病稳定12例(35.3%),疾病进展2例(5.9%),有效率为58.8%,中位疾病进展时间13.8月。常见的不良反应主要为骨髓抑制、胃肠道反应、手足综合征等。结论含卡培他滨方案治疗蒽环类和(或)紫杉类药物治疗后复发转移乳腺癌疗效确切,毒性可耐受,是治疗复发转移性乳腺癌的较好方案。
Objective To investigate the efficacy and adverse reactions of capecitabine regimen in patients with recurrent metastatic breast cancer after anthracycline and (or) taxane treatment. Methods Seventy patients with recurrent metastatic breast cancer after anthracycline and (or) taxane treatment were divided into two groups: capecitabine combined with vinorelbine (NX group, 36 cases), capecitabine 800 ~ 1000 mg / m2, divided into two morning and evening, the first to 14 days, vinorelbine 25mg / m2, the first day and the eighth day, intravenous infusion, 3 weeks for a cycle. Capecitabine combined with gemcitabine (GX group, 34 cases), capecitabine 800 ~ 1000mg / m2, in the morning and evening twice, taking the first to 14 days, gemcitabine 1g / m2, intravenous drip, the first day and the 8 days, 3 weeks for a cycle. Evaluation of the efficacy of every two cycles, were treated for at least 2 cycles or more. Results Among the patients in NX group, the complete response rate was 1 case (2.8%), 20 cases (55.6%) partially alleviated, 11 cases (30.6%) were stable, and 4 cases (11.1%) had disease progression. The effective rate was 58.3% The disease progression time was 13.5 months. Complete remission was achieved in 1 case (2.9%), partial remission in 19 cases (55.9%), stable disease in 12 cases (35.3%) and disease progression in 2 cases (5.9%), with an effective rate of 58.8% Bit disease progression time of 13.8 months. Common adverse reactions are mainly bone marrow suppression, gastrointestinal reactions, hand-foot syndrome and so on. Conclusion The curative effect of capecitabine regimen in treating recurrence and metastasis of breast cancer after anthracycline and (or) taxane treatment is effective and tolerable. It is a good treatment for recurrent breast cancer.